Stevens Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,003
| Closed | -$231K | – | 357 |
|
|
2024
Q3 | $231K | Buy |
+2,003
| New | +$231K | 0.03% | 188 |
|
|
2020
Q1 | – | Sell |
-4,692
| Closed | -$504K | – | 280 |
|
|
2019
Q4 | $504K | Buy |
4,692
+659
| +16% | +$70.8K | 0.05% | 348 |
|
|
2019
Q3 | $363K | Buy |
+4,033
| New | +$363K | 0.03% | 422 |
|
|
2019
Q1 | – | Sell |
-3,572
| Closed | -$255K | – | 821 |
|
|
2018
Q4 | $255K | Sell |
3,572
-8,864
| -71% | -$633K | 0.01% | 594 |
|
|
2018
Q3 | $1.53M | Buy |
+12,436
| New | +$1.53M | 0.06% | 354 |
|
|
2018
Q2 | – | Sell |
-20,310
| Closed | -$1.68M | – | 914 |
|
|
2018
Q1 | $1.68M | Buy |
+20,310
| New | +$1.68M | 0.06% | 320 |
|
|
2017
Q2 | – | Sell |
-27,508
| Closed | -$1.19M | – | 988 |
|
|
2017
Q1 | $1.19M | Buy |
+27,508
| New | +$1.19M | 0.05% | 384 |
|
|
2016
Q4 | – | Sell |
-14,961
| Closed | -$758K | – | 1030 |
|
|
2016
Q3 | $758K | Buy |
+14,961
| New | +$758K | 0.03% | 485 |
|
|
2015
Q4 | – | Sell |
-12,189
| Closed | -$485K | – | 1059 |
|
|
2015
Q3 | $485K | Buy |
+12,189
| New | +$485K | 0.02% | 542 |
|
|
2014
Q3 | – | Sell |
-11,481
| Closed | -$170K | – | 1165 |
|
|
2014
Q2 | $170K | Buy |
+11,481
| New | +$170K | ﹤0.01% | 954 |
|
|
2014
Q1 | – | Sell |
-22,439
| Closed | -$210K | – | 1238 |
|
|
2013
Q4 | $210K | Buy |
+22,439
| New | +$210K | 0.01% | 898 |
|